Clinical Trial Update: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating oral ladarixin in patients with recent-onset type 1 diabetes and low residual beta-cell function has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Ladarixin (ladarixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Recent Onset type1 Diabetes | Phase 2 | Status: TERMINATED